Department of Medical Imaging, Sunnybrook Health Sciences Center, University of Toronto, Canada.
Department of Radiation Oncology, Sunnybrook Health Sciences Center, University of Toronto, Canada.
Radiother Oncol. 2021 Mar;156:258-265. doi: 10.1016/j.radonc.2020.12.037. Epub 2021 Jan 5.
Prediction of early progression in glioblastoma may provide an opportunity to personalize treatment. Simplified intravoxel incoherent motion (IVIM) MRI offers quantitative estimates of diffusion and perfusion metrics. We investigated whether these metrics, during chemoradiation, could predict treatment outcome.
38 patients with newly diagnosed IDH-wildtype glioblastoma undergoing 6-week/30-fraction chemoradiation had standardized post-operative MRIs at baseline (radiation planning), and at the 10th and 20th fractions. Non-overlapping T1-enhancing (T1C) and non-enhancing T2-FLAIR hyperintense regions were independently segmented. Apparent diffusion coefficient (ADC, ADC) and perfusion fraction (f, f) maps were generated with simplified IVIM modelling. Parameters associated with progression before or after 6.9 months (early vs late progression, respectively), overall survival (OS) and progression-free survival (PFS) were investigated.
Higher ADC at baseline [Odds Ratio (OR) = 1.06, 95% CI 1.01-1.15, p = 0.025], lower f at fraction 10 (OR = 2.11, 95% CI 1.04-4.27, p = 0.018), and lack of increase in ADC at fraction 20 compared to baseline (OR = 1.12, 95% CI 1.02-1.22, p = 0.02) were associated with early progression. Combining ADC at baseline, f at fraction 10, ECOG and MGMT promoter methylation status significantly improved AUC to 90.3% compared to a model with only ECOG and MGMT promoter methylation status (p = 0.001). Using multivariable analysis, neither IVIM metrics were associated with OS but higher f at fraction 10 (HR = 0.72, 95% CI 0.56-0.95, p = 0.018) was associated with longer PFS.
ADC at baseline, its lack of increase from baseline to fraction 20, or f at fraction 10 significantly predicted early progression. f at fraction 10 was associated with PFS.
预测胶质母细胞瘤的早期进展可能为个体化治疗提供机会。简化的体素内不相干运动(IVIM)MRI 提供了扩散和灌注指标的定量估计。我们研究了这些指标在放化疗期间是否可以预测治疗结果。
38 例新诊断为 IDH 野生型胶质母细胞瘤的患者在接受 6 周/30 次放化疗后,在基线(放射治疗计划)、第 10 次和第 20 次放疗时进行了标准的术后 MRI。独立分割非重叠 T1 增强(T1C)和非增强 T2-FLAIR 高信号区域。使用简化的 IVIM 模型生成表观扩散系数(ADC,ADC)和灌注分数(f,f)图。研究与 6.9 个月前(早进展)或之后(晚进展)、总生存期(OS)和无进展生存期(PFS)相关的参数。
基线时 ADC 较高(优势比[OR]为 1.06,95%置信区间 1.01-1.15,p=0.025),第 10 次放疗时 f 较低(OR 为 2.11,95%置信区间 1.04-4.27,p=0.018),与基线相比,第 20 次放疗时 ADC 无增加(OR 为 1.12,95%置信区间 1.02-1.22,p=0.02)与早进展相关。将基线时的 ADC、第 10 次放疗时的 f、ECOG 和 MGMT 启动子甲基化状态相结合,与仅使用 ECOG 和 MGMT 启动子甲基化状态的模型相比,AUC 显著提高至 90.3%(p=0.001)。多变量分析显示,IVIM 指标均与 OS 无关,但第 10 次放疗时 f 较高(HR 为 0.72,95%置信区间 0.56-0.95,p=0.018)与较长的 PFS 相关。
基线时的 ADC、从基线到第 20 次放疗的增加缺失或第 10 次放疗时的 f 显著预测了早进展。第 10 次放疗时的 f 与 PFS 相关。